PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression

This paper investigates the therapeutic use of PCSK9 inhibitors, particularly Evolocumab, as monoclonal antibodies for the treatment of atherosclerosis based on recent literature reviews. PCSK9 is an outstanding example of a breakthrough in medical science, with advancements in understanding its bio...

Full description

Saved in:

Bibliographic Details
Main Author:	Maram H. Abduljabbar
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Pharmaceuticals
Subjects:	PCSK9 inhibitors Evolocumab atherosclerosis
Online Access:	https://www.mdpi.com/1424-8247/17/12/1581
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial
by: Xiaohui Qiu, et al.
Published: (2024-12-01)

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
by: José Seijas-Amigo, et al.
Published: (2021-05-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

Carotenoid Interactions with PCSK9: Exploring Novel Cholesterol-Lowering Strategies
by: Alessandro Medoro, et al.
Published: (2024-11-01)

PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk
by: Radosław Szydłowski, et al.
Published: (2024-12-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
by: Xue-Ying Zhang, et al.
Published: (2025-02-01)

MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes
by: Xuemei Chen, et al.
Published: (2024-11-01)

Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions
by: Li J, et al.
Published: (2024-12-01)

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
by: Shengxuan Zhang, et al.
Published: (2024-11-01)

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
by: Yuhua Jiang, et al.
Published: (2025-02-01)

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
by: Ewelina Jakielska, et al.
Published: (2023-03-01)

Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study—Preliminary Results
by: Ziv Rosman, et al.
Published: (2024-10-01)

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China
by: Xing Gong, et al.
Published: (2025-01-01)

Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023
by: Ping Lai, et al.
Published: (2024-11-01)

Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases
by: Roshan R. Rughwani, et al.
Published: (2022-09-01)

PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro
by: Jiancheng Lin, et al.
Published: (2024-12-01)

RETRACTED ARTICLE: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
by: Khursheed Muzammil, et al.
Published: (2024-03-01)

Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies
by: Chen Gurevitz, et al.
Published: (2024-12-01)

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia
by: Grzegorz Porebski, et al.
Published: (2024-02-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

Evolocumab safety and efficacy in hypercholesteremia patients with or without diabetes: a retrospective real-world analysis
by: Sultan Ibrahim Alraddadi, et al.
Published: (2025-01-01)

Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
by: Emilie Wong Chong, et al.
Published: (2022-10-01)

Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers
by: Ping Jin, et al.
Published: (2025-01-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Aerobic exercise alleviates statin-induced PCSK9 upregulation by increasing epoxyeicosatrienoic acid levels through the FoxO3a–Sirt6 axis
by: Jiahui Hu, et al.
Published: (2025-12-01)

Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review
by: Nashmil Ghadimi, et al.
Published: (2024-01-01)

The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes
by: Zeki Dogan, et al.
Published: (2025-02-01)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study
by: Koutaro Yokote, et al.
Published: (2024-11-01)

Real-World Application of Evolocumab Among Patients with Hyperlipidemia in Korea: A Multicenter Prospective Study
by: Min Chul Kim, et al.
Published: (2024-10-01)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
by: Frederick Berro Rivera, MD, et al.
Published: (2025-02-01)

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
by: Wenhui Hu, et al.
Published: (2025-12-01)

Familial Hypercholesterolemia: Genetics, Symptoms, Diagnosis and Treatment - A Literature Overview
by: Maciej Rutkiewicz, et al.
Published: (2025-02-01)

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review
by: Fang Jia, et al.
Published: (2025-01-01)

Effect of Eriobotrya japonica L. (Chinese medicinal plant) on the regulation of lipid metabolism in atherosclerosis-induced mice and in HepG-2 cells
by: Imane Mokhtari, et al.
Published: (2024-12-01)

Annexin A8 deficiency delays atherosclerosis progression
by: Carmen Gutiérrez‐Muñoz, et al.
Published: (2025-01-01)

The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)

Bacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis
by: Yuling Lin, et al.
Published: (2025-12-01)